VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Metrics to compare | VBIVQ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVBIVQPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −7.5x | −0.6x | |
PEG Ratio | 0.00 | 0.06 | 0.00 | |
Price / Book | 0.0x | 2.3x | 2.6x | |
Price / LTM Sales | 0.0x | 25.0x | 3.2x | |
Upside (Analyst Target) | - | 52.9% | 40.6% | |
Fair Value Upside | Unlock | 2.8% | 7.1% | Unlock |